Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.

Authors: Wang, Jianlin; Yu, Qian; Qiu, Zhaoping; Dai, Tao; Wang, Shuxia; Yang, Xiuwei; Evers, B Mark; Wu, Yadi

Published In Aging (Albany NY), (2020 Jan 05)

Abstract: Epigenetic modifications play an important role in prostate tumor development and progression. Epigenetic drugs are emerging as effective modulators of gene expression that act on pathways potentially important in the control of cancer clinically. We investigated two different epigenetic modulating drugs, SP-2509 and JQ1, that target histone lysine demethylase 1 (LSD1), and bromodomain-containing protein (BRD), respectively and their combined effect in three different prostate cancer (PCa) types: 1) androgen receptor (AR)-positive and androgen-sensitive; 2) AR-positive but castration-resistant; and 3) androgen-nonresponsive. We found combined treatment provided a synergistic growth inhibition in castration-resistant PCa cells but knockdown of AR reduced sensitivity to both inhibitors in these cells. In the androgen-sensitive cell lines, AR knockdown attenuated sensitivity to the LSD1 inhibitor but not the JQ1 inhibitor. Strikingly, treatment with SP-2509 slightly, and JQ1 markedly increased invasion in PCa cells with high AR expression but decreased invasion in PCa cells with low/negative AR expression. Our results suggest that these two epigenetic drugs are novel and promising compounds for the development of PCa therapeutics, particularly for castration-resistant disease. However, due to the potential risks, including metastasis, caution must be exercised in the clinical setting.

PubMed ID: 31901895 Exiting the NIEHS site

MeSH Terms: Animals; Apoptosis/genetics; Azepines/pharmacology; Cell Cycle Proteins/genetics; Cell Cycle Proteins/metabolism*; Cell Line, Tumor; Epigenesis, Genetic*; Gene Expression Regulation, Neoplastic*/drug effects; Gene Knockdown Techniques; Histone Demethylases/genetics; Histone Demethylases/metabolism*; Humans; Male; Prostatic Neoplasms, Castration-Resistant/genetics; Prostatic Neoplasms, Castration-Resistant/metabolism; Prostatic Neoplasms, Castration-Resistant/pathology; Prostatic Neoplasms/genetics*; Prostatic Neoplasms/metabolism*; Prostatic Neoplasms/pathology; Receptors, Androgen/metabolism; Transcription Factors/genetics; Transcription Factors/metabolism*; Triazoles/pharmacology

Back
to Top